Briefly, late-stage clinical study results on these advanced immunity-based anti-cancer therapeutics have been disappointing despite their promising non-clinical and earlier phase clinical study results, which included, among others, a MUC1 antigen-specific Tecemotide [91] (Merck KGaA, Darmstadt), MAGE-A3 antigen-specific cancer immunotherapeutics [92] (GSK, London), and an hTERT epitope-specific peptide vaccine GV1001 [93] (Kael & Gemvax, Seoul). This evidence concerns the gene MUC1 and cancer.